Literature DB >> 18971789

Biochemical mechanism of acetylsalicylic acid (Aspirin) selective toxicity toward melanoma cell lines.

Nikhil M Vad1, Garret Yount, Majid Y Moridani.   

Abstract

In the current work, we investigated the biochemical toxicity of acetylsalicylic acid (ASA; Aspirin) in human melanoma cell lines using tyrosinase enzyme as a molecular cancer therapeutic target. At 2 h, ASA was oxidized 88% by tyrosinase. Ascorbic acid and NADH, quinone reducing agents, were significantly depleted during the enzymatic oxidation of ASA by tyrosinase to quinone. The 50% inhibitory concentration (48 h) of ASA and salicylic acid toward SK-MEL-28 cells were 100 micromol/l and 5.2 mmol/l, respectively. ASA at 100 micromol/l was selectively toxic toward human melanocytic SK-MEL-28, MeWo, and SK-MEL-5 and murine melanocytic B16-F0 and B16-F10 melanoma cell lines. However, ASA was not significantly toxic to human amelanotic C32 melanoma cell line, which does not express tyrosinase enzyme, and human nonmelanoma BJ, SW-620, Saos, and PC-3 cells. Dicoumarol, a diaphorase inhibitor, and 1-bromoheptane, a GSH depleting agent, increased ASA toxicity toward SK-MEL-28 cells indicating quinone formation and intracellular GSH depletion played important mechanistic roles in ASA-induced melanoma toxicity. Ascorbic acid, a quinone reducing agent, and GSH, an antioxidant and quinone trap substrate, prevented ASA cell toxicity. Trifluoperazine, inhibitor of permeability transition pore in mitochondria, prevented ASA toxicity. ASA led to significant intracellular GSH depletion in melanocytic SK-MEL-28 melanoma cells but not in amelanotic C32 melanoma cells. ASA also led to significant reactive oxygen species (ROS) formation in melanocytic SK-MEL-28 melanoma cells but not in amelanotic C32 melanoma cells. ROS formation was exacerbated by dicoumarol and 1-bromoheptane in SK-MEL-28. Our investigation suggests that quinone species, intracellular GSH depletion, ROS formation, and mitochondrial toxicity significantly contributed toward ASA selective toxicity in melanocytic SK-MEL-28 melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18971789     DOI: 10.1097/CMR.0b013e3283107df7

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  17 in total

Review 1.  Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Authors:  Joanne M Jeter; Tawnya L Bowles; Clara Curiel-Lewandrowski; Susan M Swetter; Fabian V Filipp; Zalfa A Abdel-Malek; Larisa J Geskin; Jerry D Brewer; Jack L Arbiser; Jeffrey E Gershenwald; Emily Y Chu; John M Kirkwood; Neil F Box; Pauline Funchain; David E Fisher; Kari L Kendra; Ashfaq A Marghoob; Suephy C Chen; Michael E Ming; Mark R Albertini; John T Vetto; Kim A Margolin; Sherry L Pagoto; Jennifer L Hay; Douglas Grossman; Darrel L Ellis; Mohammed Kashani-Sabet; Aaron R Mangold; Svetomir N Markovic; Frank L Meyskens; Kelly C Nelson; Jennifer G Powers; June K Robinson; Debjani Sahni; Aleksandar Sekulic; Vernon K Sondak; Maria L Wei; Jonathan S Zager; Robert P Dellavalle; John A Thompson; Martin A Weinstock; Sancy A Leachman; Pamela B Cassidy
Journal:  Cancer       Date:  2018-10-03       Impact factor: 6.860

2.  Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells.

Authors:  Kevin M Poindexter; Susanne Matthew; Ida Aronchik; Gary L Firestone
Journal:  Cell Biol Toxicol       Date:  2016-04-07       Impact factor: 6.691

Review 3.  Use of Polyphenolic Compounds in Dermatologic Oncology.

Authors:  Adilson Costa; Michael Yi Bonner; Jack L Arbiser
Journal:  Am J Clin Dermatol       Date:  2016-08       Impact factor: 7.403

4.  Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines.

Authors:  Shashi K Kudugunti; Nikhil M Vad; Amanda J Whiteside; Bhakti U Naik; Mohd A Yusuf; Kalkunte S Srivenugopal; Majid Y Moridani
Journal:  Chem Biol Interact       Date:  2010-06-04       Impact factor: 5.192

5.  Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative.

Authors:  Christina A Gamba; Susan M Swetter; Marcia L Stefanick; Jessica Kubo; Manisha Desai; Katrina M Spaunhurst; Animesh A Sinha; Maryam M Asgari; Susan Sturgeon; Jean Y Tang
Journal:  Cancer       Date:  2013-03-11       Impact factor: 6.860

6.  Structure-toxicity relationship of phenolic analogs as anti-melanoma agents: an enzyme directed prodrug approach.

Authors:  Nikhil M Vad; Prabodh K Kandala; Sanjay K Srivastava; Majid Y Moridani
Journal:  Chem Biol Interact       Date:  2009-11-26       Impact factor: 5.192

Review 7.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

8.  Efficacy of caffeic acid phenethyl ester (CAPE) in skin B16-F0 melanoma tumor bearing C57BL/6 mice.

Authors:  Shashi K Kudugunti; Nikhil M Vad; Ehi Ekogbo; Majid Y Moridani
Journal:  Invest New Drugs       Date:  2009-10-21       Impact factor: 3.850

9.  Efficacy of acetylsalicylic acid (aspirin) in skin B16-F0 melanoma tumor-bearing C57BL/6 mice.

Authors:  Nikhil M Vad; Shashi K Kudugunti; Hezhen Wang; G Jayarama Bhat; Majid Y Moridani
Journal:  Tumour Biol       Date:  2014-02-04

Review 10.  Aspirin and other NSAIDs as chemoprevention agents in melanoma.

Authors:  James R Goodman; Douglas Grossman
Journal:  Cancer Prev Res (Phila)       Date:  2014-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.